iBio, Inc. (IBIO)
NASDAQ: IBIO · Real-Time Price · USD
0.8429
-0.0214 (-2.48%)
At close: Sep 17, 2025, 4:00 PM EDT
0.8620
+0.0191 (2.27%)
After-hours: Sep 17, 2025, 7:46 PM EDT
iBio, Inc. Revenue
In the fiscal year ending June 30, 2025, iBio, Inc. had annual revenue of $400.00K with 77.78% growth. iBio, Inc. had revenue of $200.00K in the quarter ending June 30, 2025, with 14.29% growth.
Revenue (ttm)
$400.00K
Revenue Growth
+77.78%
P/S Ratio
22.69
Revenue / Employee
$25,000
Employees
16
Market Cap
16.57M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 400.00K | 175.00K | 77.78% |
| Jun 30, 2024 | 225.00K | - | - |
| Jun 30, 2023 | - | - | - |
| Jun 30, 2022 | 1.88M | -487.00K | -20.54% |
| Jun 30, 2021 | 2.37M | 733.00K | 44.75% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
IBIO News
- 12 days ago - iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 23 days ago - iBio Announces Closing of $50 Million Public Offering - GlobeNewsWire
- 4 weeks ago - iBio Announces Pricing of $50 Million Public Offering - GlobeNewsWire
- 4 weeks ago - iBio Announces Proposed Public Offering - GlobeNewsWire
- 3 months ago - iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results - GlobeNewsWire
- 3 months ago - iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call - GlobeNewsWire
- 3 months ago - iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment - GlobeNewsWire
- 4 months ago - iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model - GlobeNewsWire